We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Compact AI-Powered Microscope Enables Rapid Cost-Effective Cancer Scoring

By LabMedica International staff writers
Posted on 04 Sep 2025

Digital pathology is essential for modern cancer diagnostics, particularly for evaluating biomarkers like HER2, which guide breast cancer treatment decisions. More...

However, conventional whole-slide imaging scanners are prohibitively expensive, costing over USD 100,000, and their large size limits use in many labs and resource-limited settings. To address these challenges, researchers have now developed a compact scanning microscope that uses artificial intelligence (AI) to extract diagnostic value from blurred tissue images at a fraction of the cost.

BlurryScope, a portable, cost-effective scanning microscope, has been designed by researchers at UCLA (Los Angeles, CA, USA) for HER2 scoring in breast cancer tissue samples. Built for under USD 650 and weighing just 2.26 kg, the device measures 35 x 35 x 35 cm, making it highly accessible. Unlike conventional microscopes that capture sharp still images, BlurryScope continuously scans slides, producing motion-blurred images that are then analyzed by a deep neural network trained to classify HER2 expression.

In blinded experiments with 284 patient tissue cores, the system achieved nearly 80% accuracy across standard HER2 scoring categories and almost 90% accuracy when grouped into clinically actionable categories. Repeated scans of the same samples demonstrated reproducibility, with more than 86% of classifications matching across multiple runs. The results, published in npj Digital Medicine, validate both the robustness of the AI and the reliability of the device for clinical application.

BlurryScope automates the workflow from scanning to classification, enabling rapid triage, preliminary assessments, and use in clinics where high-end systems are impractical. Beyond HER2 scoring, the same AI-powered approach could extend to other tissue stains, biomarker analyses, and even different imaging modalities. By co-designing optical systems and AI algorithms, the technology demonstrates a pathway toward simplifying biomedical imaging hardware while broadening diagnostic access worldwide.

“With BlurryScope, we are redefining what affordable microscopy can look like,” said Dr. Aydogan Ozcan, Chancellor’s Professor of Electrical and Computer Engineering at UCLA. “By harnessing deep learning to interpret motion-blurred images, we can deliver clinically meaningful HER2 scoring at a fraction of the cost and size of conventional pathology scanners.”

Related Links:
UCLA


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.